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Abstract 
Purpose: Corticosteroids remain the mainstay therapy for uveitis, a major cause of blindness 
in the working age population. However, a substantial number of patients cannot benefit from 
the therapy due to steroids resistance or intolerance. Tacrolimus has been used to treat 
refractory uveitis through systemic administration. The aim of this study was to evaluate the 
therapeutic potential of 0.03% tacrolimus eyedrop in mouse models of uveitis.  
Methods: 0.03% tacrolimus in perfluorobutylpentane (F4H5) (0.03% Tacrolimus/SFA) was 
formulated using a previously published protocol. Tacrolimus suspended in PBS (0.03% 
Tacrolimus/PBS) was used as a control. In addition, 0.1% dexamethasone (0.1% DXM) was 
used as a standard therapy control. Endotoxin-induced uveitis (EIU) and experimental 
autoimmune uveoretinitis (EAU) were induced in adult C57BL/6 mice using protocols 
described previously. Mice were treated with eyedrops three times/day immediately after EIU 
induction for 48h or from day 14 to day 25 post-immunization (for EAU). Clinical and 
histological examinations were conducted at the end of the experiment. Pharmacokinetics study 
was conducted in mice with and without EIU. At different times after eyedrop treatment, ocular 
tissues were collected for tacrolimus measurement.  
Results: The 0.03% Tacrolimus/SFA eyedrop treatment reduced the clinical scores and 
histological scores of intraocular inflammation in both EIU and EAU to the levels similar to 
0.1% DXM eyedrop treatment. The 0.03% Tacrolimus/PBS did not show any suppressive 
effect in EIU and EAU. Pharmacokinetic studies showed that 15 min after topical 
administration of 0.03% Tacrolimus/SFA, low levels of tacrolimus were detected in the retina 
(48 ng/g tissue) and vitreous (2.5 ng/ml) in normal mouse eyes, and the levels were 
significantly higher in EIU eyes (102 ng/g tissue in the retina and 24 ng/ml in the vitreous). 
Tacrolimus remained detectable in intraocular tissues of EIU eyes 6h after topical 
 
 
administration (68 ng/g retinal tissue, 10 ng/ml vitreous). Only background levels of tacrolimus 
were detected in the retina (2-8 ng/g tissue) after 0.03% Tacrolimus/PBS eyedrop 
administration.  
Conclusion: 0.03% Tacrolimus/SFA eyedrop can penetrate ocular barrier and reach 
intraocular tissue at therapeutic levels in mouse eyes, particularly under inflammatory 
conditions. 0.03% Tacrolimus/SFA eyedrop may have therapeutic potentials for inflammatory 
eye diseases including uveitis.     
  
 
 
Introduction 
Uveitis is an inflammatory condition of the uveal tract of the eye. Clinically, it can be classified 
into anterior, intermediate, posterior and pan uveitis based on the part of the uveal tract affected. 
Anterior uveitis accounts for 60-80% of all uveitis cases [1,2]. Uveitis remains a significant 
cause of blindness in people of working age accounting for 10–15% of total blindness in the 
USA [3]. Uveitis can have infectious or non-infectious (autoimmune) aetiologies. A recent 
study has shown that the prevalence of non-infections uveitis in the USA is 121 people per 
100,000 for adults and 29 per 100,000 for children [4]. However, in Southern India, it has been 
reported that nearly one in 200 persons may be affected by this condition [5].  
Autoimmune uveitis is mediated by retinal antigen specific T lymphocytes, including Th1 and 
Th17 cells [6,7], and corticosteroids remain the mainstay therapy for this condition. Anterior 
uveitis is treated with topical steroids, although systemic immune suppression may be required 
if patients also have other systemic autoimmune conditions. For posterior uveitis, apart from 
systemic immune suppression, intravitreal injection of steroids (e.g., dexamethasone, 
triamcinolone and fluocinolone) is now commonly used. Various intraocular implants have 
also been developed to improve intraocular drug delivery. Although intravitreal injection of 
steroids can better control inflammation [8] and cause limited systemic side-effects, local 
adverse effects remain a major concern. For example, 30-50% of patients developed glaucoma 
following intravitreal injection of triamcinolone [9]; almost all patients received intravitreal 
injections of fluocinolone via the Retisert implant had glaucoma and 40% of them required 
surgery to control the pressure [8]. Cataract is another common side-effect, particularly in 
patients receiving multiple intravitreal steroid injections [10]. Clearly, more effective and safer 
therapies are urgently needed for uveitis. 
 
 
Tacrolimus (FK506), a macrolide lactone isolated from fungus, Streptomyces tsukubaensis is 
a potent immunosuppressive drug [11]. Tacrolimus has the same mechanical action of 
inhibiting T-lymphocyte signal transduction and cell proliferation as cyclosporine, but is 100 
times more powerful [12-14]. Tacrolimus is used off label as a second line of therapy for uveitis 
through systemic administration and is proved to be effective, particularly in steroid-resistance 
or intolerance patients [15-17]. However, long-term usage can cause tacrolimus intolerance 
due to severe adverse effects (e.g., nephrotoxicity, hypertension, hyperesthesia, muscular 
weakness, insomnia, and central nervous system alterations, etc. [18]). Topical formulations of 
tacrolimus are not available due to the poor solubility and stability of the molecule in aqueous 
environments.  
Semifluorinated alkanes (SFAs) are physically, chemically and physiologically inert, undergo 
neither catabolism nor metabolism in the human body and have favourable physical properties 
for use in the eye, including low surface and interface tension leading to excellent spreading 
properties [19]. Moreover, lipophilic drugs such as tacrolimus can be formulated without the 
use of surfactants and stabilizers. These properties make them ideal for ocular drug delivery 
[20]. Among the various SFAs, we explored perfluorobutylpentane (F4H5) for ophthalmic 
applications. Here we report the therapeutic potential of a novel formula of tacrolimus eyedrop 
i.e., 0.03% tacrolimus dissolved in F4H5, in mouse models of uveitis, including the endotoxin-
induced uveitis (EIU), a model of human anterior uveitis, and retinal antigen peptide induced 
experimental autoimmune uveoretinitis (EAU), a model of human posterior uveitis.  
 
Material and Methods 
Animals  
 
 
Ten- to 12-week-old C57BL/6J mice were supplied by the Biological Resource Unit at the 
Queen’s University Belfast. All procedures adopted conformed to the Home Office 
Regulations for Animal (Scientific Procedures) Act 1986 (UK) and to the Association for 
Research in Vision and Ophthalmology Statement for the use of Animals in Ophthalmic and 
Vision Research. All protocols were approved by the Ethics Committee of the Queen’s 
University Belfast.   
Induction of Experimental Autoimmune Uveoretinitis (EAU)  
EAU was induced as previously described [21-23]. Briefly C57BL/6J mice were immunized 
subcutaneously with 500 µg of IRPB peptide 1–20 (GPTHLFQPSLVLDMAKVLLD; GL 
Biochem, Shanghai Ltd, China) emulsified in complete Freund’s adjuvant (CFA, H37Ra, Difco 
Laboratories, Detroit, MI, USA). Mice were administered with an additional intraperitoneal 
injection of 100 µl (1.5 µg) of Bordetella pertussis toxin (Tocris Bioscience, UK). Retinal 
inflammation develops at day 12-14 post-immunisation (p.i.), and peaks at day 22-25 p.i. The 
severity of inflammation declines after the peak stage, however, retinal inflammation remains 
active for over 4 months [22].  
 
Induction of Endotoxin Induced Uveitis (EIU) 
EIU was induced in C57BL/6J mice by intravitreal injection of lipopolysaccharide (LPS) using 
a previously described protocol [24,25] with slight modification. In brief, Escherichia 
coli 055:B5 LPS (Sigma, UK) was dissolved in pyrogen-free phosphate buffered saline (PBS). 
Mice were injected intravitreally with 200 ng/eye LPS in 1 µL using a 30-gage needle and a 25 
µL syringe in the Repeating Dispenser (PB600-1, Hamilton, Nevada, USA). Intraocular 
inflammation begins 4 to 6 hours after the LPS challenge, peaks at 24 - 48h, the inflammation 
then starts to resolve after 3 days [25]. 
 
 
 
Formulations 
A solution of 0.03% w/v of tacrolimus (Zhejiang Hisun Chemical CO., LTD., China) in 1.4% 
w/w ethanol (Sigma-Aldrich, Germany) in perfluorobutylpentane (F4H5) (Novaliq GmbH) 
was formulated according to the procedure detailed in relevant Patents. Tacrolimus suspended 
in PBS (0.03%) was used as a control. In addition, 0.1% dexamethasone (DXM) (Sigma-
Aldrich, UK) was used as a standard therapy control.  
 
Treatment  
Treatment of EAU: On day 14, EAU mice were divided into four groups based on the clinical 
score of inflammation and the score in each group was comparable. Group 1: Control (no 
treatment, n = 7 mice); Group 2: 0.1 % Dexamethasone eyedrop (DXM, n = 7 mice); Group 3: 
0.03% Tacrolimus/PBS eyedrop (n = 7 mice); Group 4: 0.03% Tacrolimus/SFA eyedrop (n = 
7 mice). All mice in groups 2-4 received eyedrop treatment three times a day from day 14 p.i. 
- day 25 p.i.  
Treatment of EIU: Mice were randomized into four groups in the EIU study: Group 1: Control 
(no eyedrops, n = 6 mice); Group 2: 0.1% Dexamethasone treatment, N = 6 mice; Group 3: 
0.03% Tacrolimus/PBS, n = 6 mice; Group 4: 0.03% Tacrolimus/SFA, n = 8 mice. All mice 
were treated with eyedrops three times per day starting immediately after the intravitreal 
injection of LPS for two days. The study was repeated twice. 
 
Clinical evaluation of ocular inflammation  
Animals were anesthetized by isoflurane inhalation (Vet Tech Solutions Ltd, UK) and pupils 
dilated using 1% atropine and 2.5% phenylephrine (Minims, Bausch and Lomb, UK). The 
severity of ocular inflammation was evaluated under the microscope taking into consideration 
 
 
of both anterior and poster inflammation (by fundus examination using the fundus imaging 
system). The clinical score for anterior uveitis was graded according to a previously defined 
scoring system (grades 0–4) [26]: grade 0, no inflammatory reaction; grade 1, discrete 
inflammation of the iris and conjunctival vessels; grade 2, dilation of the iris and conjunctival 
vessels with moderate flare in the anterior chamber; grade 3, hyperemia in the iris associated 
with the Tyndall effect in the anterior chamber; and grade 4, same clinical signs as for 3 plus 
the presence of fibrin or synechiae. To evaluate retinal inflammation, fundus images were taken 
from each mouse using the Topical Endoscopic Fundus Imaging (TEFI) system as described 
previously [26]. Digital images from each eye were analysed and clinical score was assessed 
by two independent researchers using a standard grading system developed by us previously 
[26].  
 
Histology 
Eyes were collected from day 25 p.i. EAU or day 2 p.i. EIU mice for histological examination. 
All eyes were fixed in 2.5% (w/v) glutaraldehyde (Agar Scientific Ltd, Stansted, UK) for at 
least 24h. Eyes were then embedded in paraffin and processed for haematoxylin and eosin 
(H&E) staining, and examined using a light microscope (Nikon Eclipse E400 light microscope; 
Nikon UK Ltd.) For each eye, four sections from four different layers 100 µm apart were 
graded according to the criteria described previously [27]. 
 
Pharmacokinetics study of Tacrolimus/SFA eyedrop 
Eyedrop treatment and groups: The pharmacokinetics of Tacrolimus/SFA eyedrop were 
conducted in both normal mice and EIU mice. Normal C57BL/6J mice or EIU mice 
(immediately after LPS injection) were treated with either 0.03% Tacrolimus/SFA or 0.03% 
 
 
Tacrolimus/PBS eyedrops (60 µL/drop) three times per day for three days. At different times 
(15 min, 30 min, 1 h, 2 h, 4 h and 6 h) after the last eyedrop treatment, animals were sacrificed 
and the following samples were collected for the measurement of tacrolimus (1) vitreous 
humour, (2) retina, (3) choroid/sclera, and (4) blood. Four mice were used in each group, and 
20 normal mice and 8 EIU mice that did not receive any eyedrop treatment were used as 
controls.  
Sample collection and processing: (1) Vitreous humour – 6 ~ 8 μL vitreous humour were 
collected from each mouse. (2) Retina – Retinal tissues were dissected and weighted 
immediately after sacrificing the animal and put into an Eppendorf tube. (3) Choroid/sclera – 
Chroroid/scleral tissues were dissected and weighted immediately after sacrificing the animal 
and put into an Eppendorf tube. (4) Blood – 200 ~ 500 μL of whole blood were collected into 
EDTA-coated tubes from each mouse.  
All samples were stored at - 20°C and then shipped to Nuvisan GmbH. Determination of 
tacrolimus was conducted at Nuvisan GmbH using an internally standardized liquid 
chromatography tandem mass spectrometry (LC-MS/MS) method, which was qualified for the 
respective matrices before sample analysis. The lower limit of quantification was 0.25 ng/mL 
for blood, 0.05 ng/mL for retina and choroid/sclera homogenate, and 1.25 ng/ml for the 
vitreous.  
 
 
Results 
 
The effect of Tacrolimus/SFA eyedrop in EIU 
 
 
Clinical investigation revealed engorgement of conjunctival vessels, massive immune cell 
infiltration in the anterior chamber and the vitreous of untreated and tacrolimus-PBS treated 
EIU mice at 48 h (arrows, Fig. 1A, B). Infiltrating cells were more frequently observed in the 
inferior part of the vitreous body (Fig. 1B). Retinal detachment and haemorrhage were 
observed in eyes with severe inflammation (arrow, Fig. 1C). The severity of intraocular 
inflammation was reduced following Dexamethasone (Fig. 1D) or Tacrolimus/SFA (Fig. 1E) 
treatment compared to control and Tacrolimus/PBS treated groups (Fig. 1F).  
Consistent with the clinical signs, histological analysis revealed marked features of EIU 
characterized by accumulation of immune cells in the anterior chamber (AC), vitreous cavity 
(Vi), and ciliary body (CB) area in mice with no treatment (Fig. 2A) or Tacrolimus/PBS 
eyedrop treatment (Fig. 2B). Severe retinal destruction (retinal detachment, disorganised 
retinal layers, haemorrhage) associated with massive retinal immune cell infiltration was also 
observed (arrows in Figs. 2A & 2B). Mild cell infiltration in the vitreous and retina was 
observed in eyes treated with DXM or Tacrolimus/SFA eyedrops, and the overall architecture 
of retinal layers remained intact (Fig. 2C, D). The histopathological scores in DXM and 
Tacrolimus/SFA treated eyes were significantly lower than that from untreated control EIU 
eyes (Fig. 2E). Repeated studies in additional two sets of mice revealed similar results. 
 
The effect of Tacrolimus/SFA eyedrop in EAU 
Having shown that Tacrolimus/SFA eyedrop suppressed inflammation in EIU, we further 
tested its therapeutic effects in EAU, a mouse model of posterior uveitis. Topical administration 
of eyedrops was started after the onset of uveitis i.e., 14 days post-immunisation (p.i.). Clinical 
scores of EAU were comparable between study groups prior to treatment (i.e., day 14). Severe 
retinal inflammation, characterised by extensive retinal infiltration (whitish lesions, Fig. 3A, & 
 
 
3B), vascular cuffing (arrows, Fig. 3A), and linear lesions (arrowhead, Fig. 3A) was observed 
in untreated and Tacrolimus/PBS treated EAU mice. Mild inflammation characterized by 
discrete small infiltrates, mild vascular cuffing and optic head swelling (Fig. 3C & 3D) was 
observed in dexamethasone and Tacrolimus/SFA treated eyes. The severity of retinal 
inflammation increased from day 14 to day 25 p.i. in all groups, although the increment was 
more significant in untreated and Tacrolimus/PBS treated groups compared to Tacrolimus/SFA 
and DXM treated groups (Fig. 3E). On day 25 p.i., the clinical scores of the DXM and 
Tacrolimus/SFA treated groups were significantly lower than those from untreated mice (Fig. 
3F).  
Histological examination revealed massive immune cell infiltration in the retina and vitreous 
in eyes from untreated (Fig. 4A) and Tacrolimus/PBS treated (Fig. 4C) mice. Retinal layers 
were disorganised in these eyes. Small numbers of immune cell infiltration and granulomatous 
lesions (arrows, Fig. 4) were observed in DXM (Fig. 4B) and Tacrolimus/SFA (Fig. 4D) treated 
eyes, although the retinal structure was largely intact in these mice. The overall 
histopathological score of EAU was significantly lower in DXM treated and Tacrolimus/SFA 
treated mice compared to untreated controls (Fig. 4E). Our results suggest that DXM and 
Tacrolimus/SFA eyedrop is effective for the control of ongoing ocular inflammation in EAU. 
Pharmacokinetics and absorption of tacrolimus eyedrop  
Pharmacokinetics and absorption of Tacrolimus eyedrop in normal non-inflamed mice: 
The levels of tacrolimus in the vitreous humour collected at 15 minutes to 2 h after 
Tacrolimus/SFA eyedrop treatment were between 2 ~ 6 ng/ml. By 4 h and 6 h, the level of 
tacrolimus was below detectable level in most of the samples in Tacrolimus/SFA treated mice. 
In Tacrolimus/PBS treated mice the Tacrolimus level was below the detectable level in all 
samples apart from those from 1h. The level of Tacrolimus in the vitreous from 
 
 
Tacrolimus/SFA group was significantly higher than those from Tacrolimus/PBS group at 1h 
after administration (Fig. 5A).  
In the choroid/sclera, high levels of tacrolimus were detected at 15 minutes to 1 h after 
Tacrolimus/SFA eyedrop administration (276 ng/g tissue ~ 337 ng/g tissue, Fig. 5B). The levels 
then reduced to 150 ng/g tissue at 2 h and 70 ng/g tissue at 6h (Fig. 5B). In eyes treated with 
Tacrolimus/PBS, 23 ng/g and 34 ng/g tissue of tacrolimus were detected between 15 min and 
1 h, and the levels reduced to 8 ng/g tissue by 6 h (Fig. 5B). The levels of tacrolimus in the 
choroid/sclera in the Tacrolimus/SFA group at all time points were significantly higher than 
those in Tacrolimus/PBS group (Fig. 5B).  
The levels of tacrolimus in the retina in the Tacrolimus/SFA were 48 ng/g tissue at 15 min after 
eyedrop administration, and increased to 90 ng/g tissue by 1 h (Fig. 5C). The levels of 
tacrolimus decreased slightly after 2 h, but remained at 53 ng/g tissue at 6 h after eyedrop 
treatment (Fig. 5C). In eyes treated with Tacrolimus/PBS, the levels of tacrolimus were 
between 2-8 ng/g tissue at all time points and were significantly lower than those in eyes treated 
with Tacrolimus/SFA (Fig. 5C). 
The level of Tacrolimus in the blood of normal mice treated with Tacrolimus/SFA increased 
from 35 ng/ml at 15 minutes to 118 ng/ml at 30 minutes and then reduced from 1 h but remained 
at 62 ng/ml at 2 h after treatment (Fig. 5D). Lower levels of tacrolimus (2 – 40 ng/ml) were 
detected in the blood in mice treated with Tacrolimus/PBS eyedrop, although the levels were 
not statistically higher than those in untreated controls mice (Fig. 5D). The blood levels of 
tacrolimus in Tacrolimus/SFA group were significantly higher than those in Tacrolimus/PBS 
group at 30 min, 1h, and 4h time points (Fig. 5D).    
 
 
Our results suggest that Tacrolimus/SFA has a greater permeability than Tacrolimus/PBS, and 
can rapidly penetrate ocular barriers in normal mouse eyes and distribute to all ocular tissues 
as well as the blood circulation rapidly (within 15 ~ 30 min) after eyedrop administration.   
Pharmacokinetics and absorption of Tacrolimus eyedrop in uveitis mice:  
Only Tacrolimus/SFA was tested in the uveitis eyes. Therefore, we compared the 
pharmacokinetics of Tacrolimus/SFA eyedrop between uveitis eyes and non-uveitis eyes. The 
levels of tacrolimus in the vitreous of uveitis mice were 24 ng/ml and 14 ng/ml at 15 min and 
30 min respectively, significantly higher than those in non-uveitis mice (2.5 ng/ml and 2.3 
ng/ml respectively). Six hours after eyedrop administration 10 ng/ml of Tacrolimus were 
detected in the vitreous of uveitis eyes compared to 1.1 ng/ml in non-uveitis eyes (Fig. 6A).  
The level of Tacrolimus in the choroid/sclera was 855.5 ng/g tissue at 15 min after eyedrop 
administration in uveitis mice compared to 276 ng/g tissue in normal mice (Fig. 6B). The 
concentrations of Tacrolimus decreased at 30 min and 1 h in uveitis eyes to the levels that were 
comparable to non-uveitis eye. At 2 h and 6 h, uveitis mice had significantly higher levels of 
Tacrolimus compared to normal non-inflamed mice (Fig. 6B).     
Significantly higher levels of tacrolimus were detected in the retina of uveitis mice compared 
to that of non-uveitis mice after 15 min (102 vs 48 ng/g tissue) and 2 h (115 ng/g vs 61 ng/g 
tissue) (Fig. 6C) of administration. The level of retinal tacrolimus at 6 h was approximately 
67% of that in 15 min in uveitis eyes (Fig. 6C).        
The blood level of Tacrolimus was to 280 ng/ml in uveitis mice 15 min after administration, 
significantly higher than that in non-uveitis mice (35ng/ml) (Fig. 6D). The levels then 
decreased in uveitis mice to 143ng/ml at 30 min and to 73ng/ml at 6h after eyedrop treatment. 
In non-inflamed mice, the blood levels of Tacrolimus increased at 30 min to the 118ng/ml, and 
remained at the levels comparable to uveitis mice at other time points (Fig. 6D).  
 
 
 
Discussion 
Oral administration of tacrolimus is effective in uveitis refractory to corticosteroids and 
cyclosporine [15-17,28]. Recent studies in non-infectious posterior uveitis patients have shown 
that tacrolimus monotherapy is as effective as the tacrolimus plus prednisone dual therapy in 
maintaining disease remission [29]. However, long-term systemic administration can cause 
tacrolimus intolerance [18]; therefore, local administration of tacrolimus would be an ideal 
option. Previous studies have demonstrated that intravitreal injection of tacrolimus is effective 
in controlling inflammation in experimental models of uveitis [30-32]. In this study, we show 
that 0.03% Tacrolimus/SFA eyedrop suppressed intraocular inflammation in both EIU and 
EAU models. Importantly, we show that Tacrolimus/SFA can rapidly penetrate ocular barrier 
at high levels, particularly in EIU eyes. Tacrolimus/PBS did not show any suppressive effect 
in EIU and EAU models, and it was unable to penetrate ocular barriers. Our results suggest that 
0.03% Tacrolimus/SFA may be a novel therapy for intraocular inflammation.       
Tacrolimus has a poor ability to penetrate tissue barrier upon topical administration due to its 
physicochemical properties [33]. Currently, a few tacrolimus formulations are being tested for 
ocular surface disorders such as allergic conjunctivitis [34-37], dry eye conditions [38], and 
high-risk corneal transplantation [39]. The formulas include 0.03% tacrolimus eye ointment 
(Protopic) and 0.03% tacrolimus eyedrop (Olive oil + 0.03% Tacrolimus, Ophthalmos Pharma, 
San Paulo, Brazil), 0.1% Tacrolimus ophthalmic suspension (Senju Pharmaceutical Co., 
Osaka, Japan), and 0.1% tacrolimus ophthalmic eye ointment (Tacimus-Ajanta 
Pharmaceuticals, India). The use of topical administration of tacrolimus to treat intraocular 
inflammation has not been reported, probably because none of the aforementioned products are 
capable of penetrating ocular barrier with therapeutic concentrations.    
 
 
Recent studies have shown that semifluorinated alkanes act as an effective carrier for lipophilic 
drug cyclosporine for topical delivery [40]. In this study, we have used formulations of 
semifluorinated alkanes to dissolve tacrolimus. This formulation allows 0.03% tacrolimus to 
be dissolved completely to form a clear solution. The pharmacokinetic study suggests that 
Tacrolimus/SFA, but not Tacrolimus/PBS could rapidly (within 15 minutes) penetrate the 
tissue barriers (e.g., epithelial, membranes and endothelial barriers) after topical administration 
and reach choroid/sclera at significant levels in normal mouse.  At the same time a significant 
level of tacrolimus was observed in blood circulation. This is most likely due to direct 
absorption of tacrolimus from the ocular surface through the conjunctival vascular network. 
High blood levels of tacrolimus (along with local absorption) might contribute to high 
concentrations of tacrolimus in the choroid/sclera. 
Absorption of tacrolimus is much increased when the eye is inflamed, and the levels of 
tacrolimus in the choroid/sclera and blood of uveitis mice were 3 and 8 times higher than those 
in non-uveitis mice 15 min after administration.  
Tacrolimus/SFA can penetrate not only general tissue barrier, but also the ocular barrier. 
Significant amounts of tacrolimus were detected in the vitreous and retina 15 min after topical 
administration and the drug remained in the retina for at least 6 h in normal mouse eyes. Further 
analysis is necessary to identify the source of intraocular tacrolimus, i.e, from the ciliary body 
and choroid or systemic blood circulation (via the inner BRB). 
The levels of tacrolimus in the vitreous and retina were 2 and 10 times higher in uveitis eye 
than those in non-uveitis eyes at 15 min after administration. The pharmacokinetic data may 
explain the therapeutic effect of 0.03% Tacrolimus/SFA in the EIU and EAU models observed 
in this study.  
 
 
A previous study in rabbit eyes using the 0.05% Tacrolimus suspension eyedrop has shown 
that the maximum concentrations of tacrolimus in the aqueous humour after a single dose and 
multiple doses of topical administrations were 31.4 ng/ml and 37 ng/ml respectively [41]. 
Another study showed that 1 h after 1% Tacrolimus suspension eyedrop treatment, the drug 
concentrations in the conjunctiva, cornea, iris, and anterior sclera were 148, 900, 120, and 145 
ng/g tissue, respectively, whereas the vitreous body concentration (Cmax) was only 1.4 ng/ml 
[42]. The present study in mice showed that 0.03% Tacrolimus eyedrop penetrates the ocular 
barrier (within 15 minutes) and reach to intraocular tissues at high levels (2 – 6 ng/ml in the 
vitreous body and 48-116ng/g tissue in the retina of normal mouse eyes).   
The blood concentration of tacrolimus detected in this study after eyedrop administration in 
mice (34 ~ 118 ng/ml in normal mice; 72 ~ 280 ng/ ml in uveitis mice) was significantly higher 
than that reported in the rabbit study (Cmax 2.7 ng/ml, after topical administration of 1% 
Tacrolimus suspension) [42]. It was also higher than that in human solid organ transplantation 
after systemic administration (trough blood concentration: 5 ~ 20 ng/ml) [43]. The 
discrepancies between our study and others may be due to the volume of eyedrop (e.g., standard 
drop size was used and not adjusted to the animal eye size), but more likely due to the higher 
penetration and large absorption area resulting from improved spreading of the 
Tacrolimus/SFA compared to 1% Tacrolimus suspension used in previous studies [42]. In our 
eyedrop formulation, tacrolimus is dissolved in SFA and therefore is available for absorption, 
whereas the undissolved tacrolimus particles in the 1% suspension might be removed from, 
instead of absorbed by, the eye. Furthermore, difference in body size and in physiology and 
anatomy of the eyes between mouse, rabbit and man has to be considered when translating the 
results to humans [44,45]. Therefore, further pharmacokinetics study in the rabbit or human 
eyes may help determine the clinical applications of 0.03% Tacrolimus/SFA in inflammatory 
ocular conditions.  
 
 
In conclusion, the data suggest that Tacrolimus/SFA is able to penetrate ocular barriers in mice, 
reach intraocular tissue at therapeutic levels and suppress retinal inflammation. Topical 
application of Tacrolimus/SFA should have a potential in the management of inflammatory 
eye diseases such as uveitis although further studies are necessary to evaluate the long-term 
safety of this eyedrop and its therapeutic effects on recurrent or chronic uveitis.  
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Figure Legends 
Figure 1. The effects of Tacrolimus/SFA eyedrop on clinical presentations of EIU.  EIU 
was induced in mice by intravitreal injection of 200ng/µl/eye LPS. Immediately after LPS 
injection, mice were treated with either 0.1% dexamethasone (DXM), or 0.03% 
Tacrolimus/PBS, or 0.03% Tacrolimus/SFA eyedrop, 3 times/day. Clinical evaluation 
including fundus images were conducted 48h after. (A-E) fundus images from untreated (A, 
C), Tacrolimus/PBS treated (C), DXM treated (D) and Tacrolimus/SFA treated (E) mice. 
Arrows in (A) and (B) indicating vitreous infiltrating cells; arrow in (C) indicating retinal 
haemorrhage. (E), clinical score of retinal inflammation in different groups. Mann-Whitney 
test.   
Figure 2. Histopathology of EIU in different groups of mice. EIU mice were treated with 
0.1% dexamethasone (DXM), or 0.03% Tacrolimus/PBS, or 0.03% Tacrolimus/SFA eyedrops 
3 times/day from day 0 to day 2. Eyes were collected on day 2 and processed for H-E staining. 
Light-microscopic images from (A) control untreated EIU mice, (B) Tacrolimus/PBS treated 
mice, (C) DXM treated mice, and (D) Tacrolimus/SFA treated mice. Arrows in (A) indicating 
retinal detachment; arrow in (B) indicating subretinal haemorrhage. (E) Histopathological 
score of retinal inflammation. One plot represents the score of one mouse (i.e., the average 
score of two eyes of a mouse). Mann-Whitney test. AC – anterior chamber; CB – ciliary body; 
Ir – iris; Vi – vitreous; Re – retina.   
Figure 3. The effects of Tacrolimus/SFA eyedrop on clinical presentation of EAU.  EAU 
was induced in C57BL/6J mice using IRBP1-20 peptide immunisation. On day 14, mice were 
treated with different eyedrops 3 times/day. Fundus images were taken on day 25 post-
immunisation from a control untreated EAU mouse (A), 0.03% Tacrolimus/PBS treated (B), 
0.1% DXM treated (C), and 0.03% Tacrolimus/SFA treated (D) mice. Arrows in (A) and (D) 
indicating vascular cuffing; arrowhead in (A) indicating linear lesion. (E), Changes in clinical 
score of EAU from day 14 p.i. to 25 p.i. in different groups. Wilcoxon matched pairs test. (F), 
Comparing of clinical score of EAU on day 25 p.i. in different groups. Mann-Whitney test.    
Figure 4. Histopathology of EAU in different groups of mice. EAU mice were treated with 
0.1% dexamethasone (DXM), or 0.03% Tacrolimus/SFA eyedrops 3 times/day from day 14 to 
day 24. Eyes were collected on day 25 and processed for H-E staining. Light-microscopic 
images of (A) control untreated EAU mice (B) DXM treated mice, (C) Tacrolimus/PBS treated 
mice, and (D) Tacrolimus/SFA treated mice. Arrows indicating granuloma lesions. (E) 
 
 
Histopathological score of retinal inflammation. One plot represents the score of one mouse 
(i.e., the average score of two eyes of a mouse). Mann-Whitney test. 
Figure 5. Tacrolimus levels in the vitreous, choroid/sclera, retina and blood of normal 
mouse eyes. Mice were given Tacrolimus/SFA or Tacrolimus/PBS eyedrop 3 times/day for 3 
days. At different times after the last eyedrop treatment samples were collected and processed 
for measurement of Tacrolimus using the liquid chromatography tandem mass spectrometry 
(LC-MS/MS) method. (A) vitreous. (B) choroid/sclera tissues. (C) retinal tissues. The level of 
tacrolimus was normalized to tissue weight in retina and choroid/sclera. (D) whole blood. Mean 
± SD. N = 4, * P<0.05, ** P < 0.01, ***P<0.001 compared to Tacrolimus/PBS treated eyes at 
the same time point, 2-way ANOVA. + P<0.05, ++ P<0.01 compared to Tacrolimus/PBS 
treated eyes at the same time point, unpaired t test. #, values below detectable in assay.  
 
Figure 6. Tacrolimus levels in the vitreous of mouse eyes with and without uveitis. Control 
non-uveitis mice and uveitis mice were given Tacrolimus/SFA eyedrop 3 times/day for 3 days. 
At different times after the last eyedrop treatment samples were collected. (A) vitreous. (B) 
choroid/sclera tissues. (C) retinal tissues. The level of tacrolimus was normalized to tissue 
weight in retina and choroid/sclera. (D) whole blood. Mean ± SD. N = 4,     * P<0.05, ** P < 
0.01, *** P < 0.001 compared to control non-uveitis eyes at the same time point. 2-way 
ANOVA.  + P<0.05, ++ P<0.01 compared to non-uveitis eyes at the same time point, unpaired 
t test. #, below detectable value in assay.  
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